Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

Novartis

Novartis is set to develop a range of prescription software applications that can be used to treat patients suffering from schizophrenia and multiple sclerosis.

The work will see the Swiss pharma company partner with Pear Therapeutics, a leading light in the emerging digital therapeutics field.

Novartis said its collaboration with Pear Therapeutics would see the partners work to “better address the full burden of their illnesses”.

Jay Bradner, president of the Novartis Institutes for Biomedical Research, said: "Psychiatric and neurodegenerative diseases place a heavy physical, mental and economic burden on patients and their families.

"With widespread adoption of digital devices, prescription digital therapeutics could potentially play an important role in future treatment models for a range of diseases with high unmet medical need."

They will look to do this by advancing the clinical development of Pear’s Thrive digital therapeutic for patients with schizophrenia.

Novartis and Pear will also jointly design and develop a new therapeutic application to address the mental health burden for patients with multiple sclerosis.

Corey McCann, president and CEO of Pear, said: "We look forward to working with Novartis, an organization known for excellence in biomedical science, to develop much needed treatments for patients suffering from schizophrenia and multiple sclerosis.

"Novartis shares our vision for prescription digital therapeutics that work alongside drugs to deliver superior patient outcomes. We believe this collaboration further supports the clinical viability of prescription digital therapeutics as an emerging treatment modality and we are poised to execute on that opportunity."

Pear's prescription digital therapeutics deliver clinically-proven treatments, such as cognitive behavioural therapy, to patients through mobile and desktop applications, and can be prescribed alongside prescription medicines.

The company’s Reset substance abuse app last year become the first FDA-approved prescription digital therapeutic to be cleared with claims of improving clinical outcomes.

Pear was also one of just nine firms picked last year for an FDA digital health pilot programme, with it lining up alongside the likes of Apple, Verily and Fitbit.

5th March 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics